Format

Send to

Choose Destination
J Neuroimmunol. 2014 Jun 15;271(1-2):66-8. doi: 10.1016/j.jneuroim.2014.03.012. Epub 2014 Mar 21.

Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis.

Author information

1
Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: william.brown@doctors.org.uk.
2
Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: peter.martin@addenbrookes.nhs.uk.
3
Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: john.thorpe@addenbrookes.nhs.uk.
4
Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: andrew.michell@addenbrookes.nhs.uk.
5
Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: ajc1020@medschl.cam.ac.uk.
6
Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: amandacox1@nhs.net.
7
Neurosciences Group, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom. Electronic address: angela.vincent@ndcn.ox.ac.uk.
8
Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: msz20@cam.ac.uk.

Abstract

Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic seizures (FBDS) and received rituximab after relapsing or refractory disease. Both cases achieved sustained clinical remission of up to 15 and 56 months respectively. Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides.

KEYWORDS:

Autoantibody; Cognition; Encephalitis; LGI1; Rituximab; VGKC

PMID:
24703099
DOI:
10.1016/j.jneuroim.2014.03.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center